★ WIDE MOAT STOCKS & COMPETITIVE ADVANTAGES ★
VOL. XCIV, NO. 247
Stock Profile
Novartis AG (NOVN) Moat Analysis
Novartis AG
NOVN · SIX Swiss Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Request update
Spot something outdated? Send a quick note and source so we can refresh this profile.
Overview
Novartis focuses on innovative medicines in cardiovascular-renal-metabolic disease, immunology, neuroscience, and oncology, plus established brands. H1 2026 net sales were USD 27,521m, up 1% reported but down 2% in constant currencies. Core operating margin was 39.4%. The moat is product-specific: patents and regulatory exclusivity protect current medicines, while radioligand manufacturing and logistics add an operating barrier in oncology. Industry regulation and clinical trials are common barriers, not Novartis-specific advantages. Generic competition created a 14-point Q2 sales headwind as Entresto and established brands fell. Kisqali, Kesimpta, Pluvicto, Scemblix, and Leqvio supplied the main growth. Pipeline failures, payer pressure, and loss of exclusivity remain the central risks.
Primary segment
Oncology
Market structure
Oligopoly
Market share
—
HHI: —
Coverage
5 segments · 8 tags
Updated 2026-08-23
Segments
Cardiovascular, Renal and Metabolic
Branded prescription pharmaceuticals for cardiovascular, renal and metabolic diseases
Revenue
12.6%
Structure
Oligopoly
Pricing
moderate
Share
—
Peers
Immunology
Specialty and biologic pharmaceuticals for immune-mediated inflammatory diseases (immunology/dermatology and related)
Revenue
19.1%
Structure
Oligopoly
Pricing
moderate
Share
—
Peers
Neuroscience
Branded prescription pharmaceuticals for neurological diseases (e.g., multiple sclerosis and related)
Revenue
12.5%
Structure
Oligopoly
Pricing
moderate
Share
—
Peers
Oncology
Oncology and hematology branded medicines (including targeted therapies and radioligand therapy)
Revenue
31%
Structure
Oligopoly
Pricing
strong
Share
—
Peers
Established Brands
Mature and often off-patent branded prescription medicines (established brands portfolio)
Revenue
24.9%
Structure
Competitive
Pricing
weak
Share
—
Peers
Moat Claims
Cardiovascular, Renal and Metabolic
Branded prescription pharmaceuticals for cardiovascular, renal and metabolic diseases
H1 2026 revenue share is exact: CRM net sales of USD 3,461m divided by USD 27,521m of total net sales. Sales fell 33% reported and 35% cc as Entresto declined 46%, more than offsetting Leqvio growth of 68% and the USD 43m Vanrafia launch contribution.
IP Choke Point
Legal
IP Choke Point
Strength
Durability
Confidence
Evidence
Patents and regulatory exclusivities protect differentiated medicines, but the H1 collapse in Entresto sales after US generic entry demonstrates that the advantage is product-specific and time-limited.
IP Choke Point moat: definition, examples, and stocks
Erosion risks
- Patent expiry / loss of exclusivity (LOE)
- Generic or biosimilar entry
- IP litigation losses or adverse settlements
Leading indicators
- Upcoming LOE and litigation calendar
- Biosimilar/generic approvals and launch timing
- Net price and volume erosion post-LOE
Counterarguments
- Competitors can innovate around patents or launch superior therapies
- Payers can accelerate switching within a class via formularies and rebates
Immunology
Specialty and biologic pharmaceuticals for immune-mediated inflammatory diseases (immunology/dermatology and related)
H1 2026 revenue share is exact: Immunology net sales of USD 5,246m divided by USD 27,521m of total net sales. Sales grew 6% reported and 3% cc; Cosentyx and Ilaris growth plus the Rhapsido launch outweighed a 19% decline in Xolair.
IP Choke Point
Legal
IP Choke Point
Strength
Durability
Confidence
Evidence
Patents and regulatory exclusivities protect differentiated medicines; economics typically compress sharply after loss of exclusivity.
IP Choke Point moat: definition, examples, and stocks
Erosion risks
- Patent expiry / loss of exclusivity (LOE)
- Generic or biosimilar entry
- IP litigation losses or adverse settlements
Leading indicators
- Upcoming LOE and litigation calendar
- Biosimilar/generic approvals and launch timing
- Net price and volume erosion post-LOE
Counterarguments
- Competitors can innovate around patents or launch superior therapies
- Payers can accelerate switching within a class via formularies and rebates
Neuroscience
Branded prescription pharmaceuticals for neurological diseases (e.g., multiple sclerosis and related)
H1 2026 revenue share is exact: Neuroscience net sales of USD 3,438m divided by USD 27,521m of total net sales. Sales grew 25% reported and 22% cc, led by Kesimpta at USD 2,588m and 31% growth; Zolgensma and Aimovig also grew. The European Commission approved one-time SMA gene therapy Itvisma on July 2, 2026.
IP Choke Point
Legal
IP Choke Point
Strength
Durability
Confidence
Evidence
Patents and regulatory exclusivities protect differentiated medicines; economics typically compress sharply after loss of exclusivity.
IP Choke Point moat: definition, examples, and stocks
Erosion risks
- Patent expiry / loss of exclusivity (LOE)
- Generic or biosimilar entry
- IP litigation losses or adverse settlements
Leading indicators
- Upcoming LOE and litigation calendar
- Biosimilar/generic approvals and launch timing
- Net price and volume erosion post-LOE
Counterarguments
- Competitors can innovate around patents or launch superior therapies
- Payers can accelerate switching within a class via formularies and rebates
Oncology
Oncology and hematology branded medicines (including targeted therapies and radioligand therapy)
H1 2026 revenue share is exact: Oncology net sales of USD 8,536m divided by USD 27,521m of total net sales. Sales grew 37% reported and 34% cc, led by Kisqali, Pluvicto, Scemblix and Fabhalta; Tafinlar plus Mekinist declined 5%. Novartis agreed on July 6 to acquire Myricx Bio, adding two lead ADC assets and an NMTi payload platform; the transaction remains subject to closing.
IP Choke Point
Legal
IP Choke Point
Strength
Durability
Confidence
Evidence
Patents and regulatory exclusivities protect multiple large oncology medicines, but protection is product- and jurisdiction-specific. Live Lutathera and Tafinlar/Mekinist litigation tempers a category-wide claim, so strength is four rather than five.
IP Choke Point moat: definition, examples, and stocks
Erosion risks
- Patent expiry / loss of exclusivity (LOE)
- Generic or biosimilar entry
- IP litigation losses or adverse settlements
Leading indicators
- Upcoming LOE and litigation calendar
- Biosimilar/generic approvals and launch timing
- Net price and volume erosion post-LOE
Counterarguments
- Competitors can innovate around patents or launch superior therapies
- Payers can accelerate switching within a class via formularies and rebates
Capex Knowhow Scale
Supply
Capex Knowhow Scale
Strength
Durability
Confidence
Evidence
Radioligand doses are custom-made and time-sensitive, so a geographically distributed production network and reliable scheduling create a modality-specific operating barrier.
Capex Knowhow Scale moat: definition, examples, and stocks
Erosion risks
- Rival radioligand networks adding regional capacity
- Isotope or other constrained-input shortages
- Manufacturing deviations delaying patient-specific doses
Leading indicators
- Share of doses administered on the planned treatment day
- New RLT site commissioning and regulatory approvals
- Pluvicto capacity and supply constraints
Counterarguments
- The network advantage applies to radioligand therapies, not the whole oncology portfolio
- Well-funded rivals can build or acquire regional production capacity
Established Brands
Mature and often off-patent branded prescription medicines (established brands portfolio)
H1 2026 revenue share is exact: Established Brands net sales of USD 6,840m divided by USD 27,521m of total net sales. Sales fell 16% reported and 19% cc as Promacta, Tasigna and Lucentis eroded sharply; USD 824m of contract-manufacturing sales grew 33% but does not establish a defensible segment moat.
Evidence
Many of our products are protected by intellectual property rights, including patents and regulatory exclusivities
Direct support that product economics depend on patents/exclusivities; loss of exclusivity invites generic/biosimilar competition.
offset by generic competition, mainly Entresto
Q2 Entresto sales fell 50% and H1 sales fell 46%, directly demonstrating post-exclusivity erosion.
Novartis is in patent litigation with manufacturers having FDA applications referencing Lutathera.
The current filing identifies both a product-specific legal barrier and a live challenge to its durability; Novartis appealed the adverse district-court decision.
Each dose of RLT is custom-made and requires precise coordination, making manufacturing reliability and proximity to treatment centers critical
Explains why ordinary contract-manufacturing capacity is not fully substitutable for the radioligand network.
the largest US RLT manufacturing network
The fifth planned US site extends a specialized coast-to-coast footprint.
Showing 5 of 6 sources.
Risks & Indicators
Erosion risks
- Patent expiry / loss of exclusivity (LOE)
- Generic or biosimilar entry
- IP litigation losses or adverse settlements
- Rival radioligand networks adding regional capacity
- Isotope or other constrained-input shortages
- Manufacturing deviations delaying patient-specific doses
Leading indicators
- Upcoming LOE and litigation calendar
- Biosimilar/generic approvals and launch timing
- Net price and volume erosion post-LOE
- Share of doses administered on the planned treatment day
- New RLT site commissioning and regulatory approvals
- Pluvicto capacity and supply constraints
Research NOVN elsewhere
Keep the research going
More Rankings & Systems
Quality Stocks
High quality stocks ranked by profitability, margins, free cash flow quality, durability, solvency, and accounting...
Stock rankingUndervalued Stocks
Undervalued stocks from the NA & Europe universe, ranked with a multi-measure value system and quality controls.
Stock rankingDividend Stocks
Dividend stocks ranked by payout yield, payout sustainability, dividend growth, quality, balance-sheet safety, risk...
Stock rankingDefensive Stocks
Defensive stocks ranked by low volatility, low beta, intermediate momentum, durable profitability, balance sheet...
Stock rankingMomentum Stocks
Momentum stocks ranked by total return momentum, relative momentum, trend confirmation, and risk-adjusted momentum...
Stock rankingConviction 10
A concentrated 10-stock strategy from the NA & Europe universe, ranked across quality, value, growth, momentum, and...
Curation & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.